311 related articles for article (PubMed ID: 33171304)
1. HDAC6 as privileged target in drug discovery: A perspective.
Pulya S; Amin SA; Adhikari N; Biswas S; Jha T; Ghosh B
Pharmacol Res; 2021 Jan; 163():105274. PubMed ID: 33171304
[TBL] [Abstract][Full Text] [Related]
2. Mercaptoacetamide: A promising zinc-binding group for the discovery of selective histone deacetylase 6 inhibitors.
Tavares MT; Kozikowski AP; Shen S
Eur J Med Chem; 2021 Jan; 209():112887. PubMed ID: 33035922
[TBL] [Abstract][Full Text] [Related]
3. Anti-cancer effects of naturally derived compounds targeting histone deacetylase 6-related pathways.
Lernoux M; Schnekenburger M; Dicato M; Diederich M
Pharmacol Res; 2018 Mar; 129():337-356. PubMed ID: 29133216
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in the discovery of potent and selective HDAC6 inhibitors.
Wang XX; Wan RZ; Liu ZP
Eur J Med Chem; 2018 Jan; 143():1406-1418. PubMed ID: 29133060
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase 2 selective inhibitors: A versatile therapeutic strategy as next generation drug target in cancer therapy.
Shetty MG; Pai P; Deaver RE; Satyamoorthy K; Babitha KS
Pharmacol Res; 2021 Aug; 170():105695. PubMed ID: 34082029
[TBL] [Abstract][Full Text] [Related]
6. Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors.
Porter NJ; Mahendran A; Breslow R; Christianson DW
Proc Natl Acad Sci U S A; 2017 Dec; 114(51):13459-13464. PubMed ID: 29203661
[TBL] [Abstract][Full Text] [Related]
7. Fragment-Based Drug Design of Selective HDAC6 Inhibitors.
Ruzic D; Djokovic N; Nikolic K
Methods Mol Biol; 2021; 2266():155-170. PubMed ID: 33759126
[TBL] [Abstract][Full Text] [Related]
8. PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia.
Gawel JM; Shouksmith AE; Raouf YS; Nawar N; Toutah K; Bukhari S; Manaswiyoungkul P; Olaoye OO; Israelian J; Radu TB; Cabral AD; Sina D; Sedighi A; de Araujo ED; Gunning PT
Eur J Med Chem; 2020 Sep; 201():112411. PubMed ID: 32615502
[TBL] [Abstract][Full Text] [Related]
9. Novel Selective Histone Deacetylase 6 (HDAC6) Inhibitors: A Patent Review (2016-2019).
He X; Li Z; Zhuo XT; Hui Z; Xie T; Ye XY
Recent Pat Anticancer Drug Discov; 2020; 15(1):32-48. PubMed ID: 32065106
[TBL] [Abstract][Full Text] [Related]
10. HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics.
Laino AS; Betts BC; Veerapathran A; Dolgalev I; Sarnaik A; Quayle SN; Jones SS; Weber JS; Woods DM
J Immunother Cancer; 2019 Feb; 7(1):33. PubMed ID: 30728070
[TBL] [Abstract][Full Text] [Related]
11. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
12. Combination of a Histone Deacetylase 6 Inhibitor and a Somatostatin Receptor Agonist Synergistically Reduces Hepatorenal Cystogenesis in an Animal Model of Polycystic Liver Disease.
Lorenzo Pisarello M; Masyuk TV; Gradilone SA; Masyuk AI; Ding JF; Lee PY; LaRusso NF
Am J Pathol; 2018 Apr; 188(4):981-994. PubMed ID: 29366679
[TBL] [Abstract][Full Text] [Related]
13. A Rational Approach for the Identification of Non-Hydroxamate HDAC6-Selective Inhibitors.
Goracci L; Deschamps N; Randazzo GM; Petit C; Dos Santos Passos C; Carrupt PA; Simões-Pires C; Nurisso A
Sci Rep; 2016 Jul; 6():29086. PubMed ID: 27404291
[TBL] [Abstract][Full Text] [Related]
14. Is dual inhibition of metalloenzymes HDAC-8 and MMP-2 a potential pharmacological target to combat hematological malignancies?
Amin SA; Adhikari N; Jha T
Pharmacol Res; 2017 Aug; 122():8-19. PubMed ID: 28501516
[TBL] [Abstract][Full Text] [Related]
15. An assessment of crucial structural contributors of HDAC6 inhibitors through fragment-based non-linear pattern recognition and molecular dynamics simulation approaches.
Banerjee S; Jana S; Jha T; Ghosh B; Adhikari N
Comput Biol Chem; 2024 Jun; 110():108051. PubMed ID: 38520883
[TBL] [Abstract][Full Text] [Related]
16. Methods for the expression, purification, and crystallization of histone deacetylase 6-inhibitor complexes.
Osko JD; Christianson DW
Methods Enzymol; 2019; 626():447-474. PubMed ID: 31606087
[TBL] [Abstract][Full Text] [Related]
17. Identification of Novel Histone Deacetylase 6-Selective Inhibitors Bearing 3,3,3-Trifluorolactic Amide (TFLAM) Motif as a Zinc Binding Group.
Kurohara T; Tanaka K; Takahashi D; Ueda S; Yamashita Y; Takada Y; Takeshima H; Yu S; Itoh Y; Hase K; Suzuki T
Chembiochem; 2021 Nov; 22(22):3158-3163. PubMed ID: 34224197
[TBL] [Abstract][Full Text] [Related]
18. Do biological activities of selective histone deacetylase 6 (HDAC6) inhibitors rely on the modification of cap group?
Liu X; Wang S; Shi X; Lu M; Wang C; Li X; Zhang Y; Jia Q; Liu H
J Mol Recognit; 2022 Dec; 35(12):e2988. PubMed ID: 36054561
[TBL] [Abstract][Full Text] [Related]
19. How Does Chirality Determine the Selective Inhibition of Histone Deacetylase 6? A Lesson from Trichostatin A Enantiomers Based on Molecular Dynamics.
Zhang Y; Ying JB; Hong JJ; Li FC; Fu TT; Yang FY; Zheng GX; Yao XJ; Lou Y; Qiu Y; Xue WW; Zhu F
ACS Chem Neurosci; 2019 May; 10(5):2467-2480. PubMed ID: 30784262
[TBL] [Abstract][Full Text] [Related]
20. A patent review of histone deacetylase 6 inhibitors in neurodegenerative diseases (2014-2019).
Shen S; Kozikowski AP
Expert Opin Ther Pat; 2020 Feb; 30(2):121-136. PubMed ID: 31865813
[No Abstract] [Full Text] [Related]
[Next] [New Search]
